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Abstract: A general and selective Pd-catalyzed cross-coupling of aromatic boronic acids with vinyl-
imidazoles is disclosed. Unlike most cross-coupling reactions, this method operates well in absence of bases
avoiding the formation of by-products. The reactivity is highly enhanced by the presence of nitrogen-based
ligands, in particular bathocuproine. The method involves MnO2 as oxidant for the oxidation Pd (0)!Pd (II), a
much weaker oxidant than previously reported in the literature. This allows for the use of reactants that possess
a multitude of functional groups. A scope and limitation study involving a series of 24 boronic acids, whereof
18 afforded TMs in yields in the range 41–95%. The disclosed method constitutes the first general method for
the oxidative Heck cross-coupling on the imidazole scaffold, which moreover operates with a selection of
other heterocycles.
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Introduction
Imidazole is an ubiquitous structural motif[1] that can
be found in numerous naturally occurring biomolecules
and man-made synthetic compounds. The imidazole
ring is found on its own in the essential amino acid
histidine and its hormone derivative histamine. More-
over, imidazole fused with a pyrimidine forms purine
that ends up in a variety of molecules ranging from the
nuclear bases adenine and guanine to the xanthines
found in coffee, tea and cocoa. This preeminence can
also be observed in medicinal chemistry, where the
imidazole ring can be found in compounds that hold a
multitude of biological activities[2] including
cytotoxic,[3] antifungal,[4] and anti-histaminic.[5] Fur-
thermore, imidazole-containing molecules have been
designed to have transversal applications across differ-
ent fields ranging from medical imaging, where 2-
nitro-imidazoles are essential probes for PET imaging
of hypoxia,[6] to the metalorganics, where NHC-ligands
are widely employed for homogenous metal catalysis
for example in olefin metathesis.[7]
Preparation of backbone substituted imidazoles has
traditionally been realized through multi-component
reactions.[8] However, during recent years functionali-
zation of positions 4 and 5 of the imidazole have been
explored, especially through Pd-catalyzed cross-cou-
pling reactions.[9] In our research group, such chemistry
has been implemented by means of mono- and di-
halogenation of the imidazole backbone,[10] which then
allowed for Suzuki,[11] Stille,[12] and Sonogashira[13]
cross-coupling reactions.
The Heck cross-coupling reaction also allows the
formation of a C  C bond. However, no organometallic
species are required, since it only involves an aromatic
halide and an olefin.[14] In spite of the greener approach
and the great atom economy, the Heck cross-coupling
normally requires high temperatures and long reaction
times to reach full conversion; furthermore, the
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selectivity between the regioisomers 1,1 and 1,2 is
often challenging to control.[15]
There have been several proposed improvements
and innovations to the classical Heck cross-coupling,
such as the decarbonylative approach[16] and the
oxidative Heck cross-coupling.[17,18] The latter involves
an organoboron reagent in place of the aromatic halide
that is used in the classical Heck cross-coupling. This
strategy replaces the first step of the catalytic cycle of
the Heck cross-coupling, the oxidative addition, with a
trans-metalation and it adds a new step in the catalytic
cycle, which is the oxidation of the palladium (0) to a
palladium (II) species. By avoiding the oxidative
addition, considered the rate-determining step of the
catalytic cycle, the oxidative Heck cross-coupling
normally requires milder conditions to achieve a full
conversion. In addition, by substantially lowering the
reaction temperature, an improved regioselectivity is
achieved.[19]
This strategy has been applied in our research group
both for a medicinal chemistry project and for up-
scaling,[20] proving the feasibility of the reaction also
when a larger quantity of reagents is requested.
Since the Heck cross-coupling on the imidazole has
been proven to be particularly challenging;[21,22] herein,
we unveil an oxidative Heck cross-coupling method
that allows formation of the 4-styryl-1H-imidazole
scaffold using moderate conditions that afford excel-
lent selectivity and high yield.
Results and Discussion
Synthesis of the Starting Material
The first step of our reaction pathway was to install a
suitable unencumbered olefin on the imidazole back-
bone. Different strategies were evaluated, see
Scheme 1. Initially we relied on a Stille coupling
reaction previously developed in our research group to
obtain target intermediate, pathway a of Scheme 1.
The Stille reaction afforded the highest yield (96%)
when the experiment was carried out on a 0.3 mmol
scale. Despite the excellent result, this approach was
soon abandoned not only because the Stille cross-
coupling presents toxicity issues regarding the organo-
tin reagent and the side Sn-containing by-products, but
also because the removal of organostannanes proved to
be challenging.[23] Reducing the purification times and
ruling out a possible interference by the tin halides was
crucial as early in our development process we
suspected their presence or absence might have a role
in explaining our initial uneven results in the succes-
sive C  C bond forming step. This led us to investigate
a second synthetic strategy, the Suzuki cross-
coupling,[24,25] that involved the same starting material
but with vinyl boronic acid pinacol ester as reagent.
This strategy was also abandoned as it gave only poor
yields (a maximum yield of 37% was attained).
Moreover, this method possessed another burden,
namely difficulties to separate starting material from
target compound.
Synthesis of 4-vinylimidazole was reported as a
thermal decarboxylation of urocanic acid,[26] pathway c
of Scheme 1. This strategy provided pure target
compound after distillation, but we were unable to
reproduce the reported yield (we achieved a maximum
yield of 9% only). A suitable compromise between the
reaction outcome and required purity of target inter-
mediate 4-vinyl-1H-imidazole was obtained by means
of the Wittig reaction using 1H-imidazole-4-carbalde-
hyde as substrate, pathway c of Scheme 1, to obtain a
yield of 52%. A similar strategy relying on carbonyl
olefination via aziridination[27] was also tested; how-
ever, it proved to be much more laborious and failed to
give any conversion.
Early Screening
The procedure for the oxidative Heck cross-coupling
was initially developed for a medicinal chemistry
project in our group, which needed access to various
molecules comprising a stilbene moiety.[20] These
results spurred us to consider this method for the late
stage functionalization of the imidazole backbone.
Even if some of the initial experiments were encourag-
ing (affording a yield of �40% conducted on 35 mg
scale), attempts to replicate the experiments revealed
Scheme 1. Syntheses of 1-PG/AUX-4-vinyl-1H-imidazole (1a–
e). (a) vinyl-Sn(Bu)3, Pd(PPh3)4, DMF, 2 h, 100 °C. (b) vinyl-
Bpin, Pd(PPh3)4, K2CO3, DMF, 18 h, 100 °C. (c) 220 °C, 18 h.
(d) t-BuOK, Me  P(Ph)3Br, THF, 3 h, 20 °C. (e) i) methyl
acetohydrazonate, MgSO4, MeOH, 60 °C; ii) Me3S(O)I, tBuOK,
MeCN, 20 °C, 2 h, then toluene, 90 °C, 16 h. (f) Oxidative Heck
cross-coupling method disclosed herein, which makes use of
Ph  B(OH)2 2 as reagent.
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irreproducible results only. In some cases, we even
observed zero conversion of the substrate, Table 1.
Experiments conducted at elevated temperature
using microwave oven or with the presence of an
inorganic base[28] failed as well.
Impurities present in the 4-vinyl-1H-imidazole
substrate (from the previous synthetic step) appeared
to be the cause of the varying success of the oxidative
Heck cross-coupling reaction. This was particularly
evident when the Stille cross-coupling was utilized in
the forerunner step to produce the vinyl-1H-imidazole
that served as substrate for the oxidative Heck cross-
coupling.
The same problem was not equally present when
the substrate 4-vinyl-1H-imidazole substrate was pro-
duced by means of the Wittig reaction, pathway d of
Scheme 1, but a general difficulty in replicating the
initial results remained. This spurred us to a more
thorough screening (Table 1) of the reaction condi-
tions. The first trials proved the importance of the
oxidant for the success of the reaction. For example,
target product was not achieved when benzoquinone
was used as an oxidant, whereas a yield of �5% only
was obtained when molecular oxygen and Ag2O were
used.
Overall, side products comprising the imidazole
scaffold were not observed (GC/LC–MS), but two
different products derived from boronic acid were
observed, namely the corresponding boroxine and the
phenol produced due to the presence of the oxidant.[29]
In contrast to observations in previous work,[18]
homocoupling took place only to a minor extent, 1–2%
(GC) only. From these initial promising screening
results, various experimental parameters and reagents
were explored with the ultimate goal of establishing a
selective and high yielding method.
Solvents
Previous reports disclosed that polar aprotic solvents
are beneficial as reaction medium for the oxidative
Heck cross-coupling reactions.[18,32] In our own solvent
screening, Figure 1a, we reached a similar conclusion
with acetonitrile and 1,4-dioxane both affording high
conversions, followed by DMF.
The only outlier proved to be DMSO that afforded
a yield of 6% only. Yields dramatically decreased
when water was added to the mixture and similarly
low results were obtained when a protic or an apolar
solvent were used as reaction medium.
Boronic Acid
Despite the excellent yields obtained when an excess
(2 equiv.) of boronic acid was used in the initial test
runs (Table 1), we wanted to investigate if such a high
amount was truly necessary to achieve the full
conversion and what was the minimum amount of
reagent needed to obtain excellent yields during the
reaction. Different experiments were carried out by
using increasingly higher amounts of boronic acid. The
results are shown in Figure 1b. High yields were
achieved already when only 1 equiv. of boronic acid
was employed; however, a slight excess (1.4 equiv.) of
the reagent afforded an excellent yield of 98%.
Catalyst
In our catalyst screening, Figure 1c, we decided to
explore the most commonly used Pd catalysts that
have been applied to the reaction. The catalyst that
afforded the best conversion was Pd(OAc)2, that
afforded yields of 98% and became our catalyst of
choice, which was consistent with previous findings.[20]
Although other Pd(II) species afforded various levels
of conversion, none gave comparable results in our
setup. No conversion was observed when Pd(0), in the
form of Pd(PPh3)4, was employed as catalyst. This was
expected as the Pd would have been in the wrong
oxidation state for the proposed reaction mechanism
(Scheme 7).
Table 1. Early screening experiments tailoring the oxidative
Heck cross-coupling to operate with imidazole as substrate.
# AUX Oxidant T[°C] t[h] L[f] Yield-%[a]
1 Tos Cu(OAc)2 50 18 L4 44
2 CH3 Cu(OAc)2 50 18 L2 0
3 Tos Cu(OAc)2 50 18 L2 0
4 Tos Cu(OAc)2 50 18 L2 38
5 Tos Cu(OAc)2 25 18 L4 0
6[b] Tos Cu(OAc)2 25 18 L4 0
7 Tos Cu(OAc)2 50 18 L4 0
8[c] Tos Cu(OAc)2 50 4 L4 0
9 Tos Cu(OAc)2 100 18 L4 0
10 Tos Benzoquinone 60 18 L4 0
11[d] Tos O2 80 18 L4 5
12[e] Tos O2 100 18 L4 0
13 Tos O2 60 4 L4 6
14 Tos O2 60 4 L1 75
[a] LC.
[b] Na2CO3 used as an additive.
[c] Used microwave oven for heating.
[d] Ag2O used as an additive.
[e] NaHCO3 used as an additive.
[f] L1, L2, and L4 are described in Figure 1h.
FULL PAPER asc.wiley-vch.de
Adv. Synth. Catal. 2020, 362, 5079–5092 © 2020 The Authors. Published by Wiley-VCH GmbH5081
Oxidant Screening
The nature of the oxidant is another crucial variable for
the reaction as portrayed in Figure 1d. Cu(OAc)2 that
has been proven to operate outstandingly with other
vinyl derivatives,[32] did not work in our setup, nor did
Benzoquinone, another common oxidant.
Oxygen proved to be a valid alternative, but our
screening confirmed MnO2 as the best agent of the
tested series. Its low cost, ease of removal, and the
high yield afforded confirmed it as our chosen standard
and led us to further investigations. In our proposed
catalytic cycle (see Scheme 5) we conjectured that
2 equiv. of MnO2 were necessary for the re-oxidation
of Pd. This appears to be confirmed as only 43%
conversion was observed when 1 equiv. was used,
compared to 93% conversion when 2 were employed
and 98% when a slight excess (3 equiv.) was utilized.
We employed MnO2 that the supplier marked as
activated, however, it is known that the presence of
moisture can affect its activity,[33] so we decided to test
if running the reaction in anhydrous conditions with a
MnO2 that was activated through heating at 150 °C for
12 h would affect the yields.
Since the reaction already proceeded in near full
conversion, we decided to test it on 1 equiv. of MnO2,
as this would make the changes in yield more apparent.
Figure 1. Screening of experimental variables: (a) type of solvent (select ACN), (b) quantity of boronic acid (utilize 1.4 equiv), (c)
type of Pd-catalyst (select Pd(OAc)2), (d) type and quantity of oxidant (utilize MnO2, 3 equiv.). Activated manganese dioxide:
MnO2 was activated by heating at 150 °C for 18 h prior use, (e) type protective/auxiliary group (select Tos), Tos, DMAS, and Trt
were isolated yields and H and Thp were measured by GC. (f) reaction temperature (utilize 100 °C), (g) reaction time (utilize 4 h),
(h) type of ligand for catalyst (select Bathocuproine L1). General procedure: 1a (221 μmol), phenyl boronic acid 2 (1.4 equiv.),
MnO2 (3 equiv.), Bathocuproine L1 (5%), Pd(OAc)2 (5%), solvent ACN (1 mL).
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As expected, the yield increased from 43% (in normal
conditions) to 50% (in anhydrous and activated
conditions) corresponding to a quantitative conversion,
highlighting how the presence of water can negatively
influence the completion of the reaction.
Auxiliary/Protective Group
The literature[30] and previous observations in our
research group[12] suggested that the N  H bond of the
imidazole ring might reduce the reactivity of the
substrate in cross-coupling reactions. For this reason,
various protective/auxiliary groups have been explored
with the goal to steer clear of potential side-reactions
and enhance the reactivity of the substrate.
The classes of commonly used protective groups
for the N  H of imidazole comprises: N-Sulfonyl
derivatives, N-alkyl/aryl derivatives, and carbamate
derivatives.[31] From these classes we selected the most
relevant examples: Tosyl (Tos), Trityl (Trt), DMAS,
Thp, and non-protected (H). The protected substrate
was in general synthetized by introducing the protec-
tive group first[12,13,32] on the 4-imidazolecarboxalde-
hyde followed by a Wittig reaction whereas 4-vinyl-
imidazole was obtained by deprotection of the N-tosyl-
4-vinylimidazole.[3] The results of the screening are
shown in Figure 1e. As expected, almost no conversion
was observed when the unprotected 4-vinylimidazole
1d was employed; however, various outcomes were
observed when different protective groups were
employed, suggesting that the group bound to the
imidazole ring plays a role in enhancing or impeding
the coupling reaction. In this regard, the protective
groups act as, and should be more correctly termed,
auxiliary groups. In our screening, we observed that
when a sulphonamide auxiliary group like Tos or a
sulfamide, like DMAS were used, the target molecules
were obtained with excellent yields.
However, when the ring N is directly connected to
a sp3-hybridized carbon, a substantial decreases in
outcomes were observed: 63% and 2% with Trt and
Thp, respectively.
Reaction Temperature
The outcome of the cross-coupling reaction was
investigated at diverse reaction temperatures, Fig-
ure 1f. Reaction temperatures in the range (70–100 °C)
were investigated. The cross-coupling reaction af-
forded yields in the range 61–98%, with the highest
achieved yield at 100 °C.
Reaction Time
A crucial experimental variable in organic synthesis is
the reaction time. In our initial study of the oxidative
Heck cross-coupling reaction, experiments were often
left overnight (18 h) and worked-up the following
morning, however once the reaction conditions were
optimized in other regards, we observed that a good
conversion to target molecule was already observable
after only one hour. The cross-coupling reaction was
thus further examined to reveal the conversion after
various point of time, t2[0 8] h, Figure 1g. This
examination revealed that some experiments reach a
yield of 66% already after only 30 min. and the yield
continued to increase until t�4 h. Decomposition of
target molecule was not observed even at prolonged
reaction time.
Leaving Group of the Arene Moiety
Although, the reaction afforded excellent yields using
a boronic acid as reagent, these are known to be
unstable at higher temperatures and subject to several
degradation pathways such as protodeboronation or
homocoupling. Even though such side products were
not observed in our investigation, we thought it would
be useful for the general applicability of the method to
investigate whether other leaving groups might be
utilized. Boronic esters are often a more stable, but
less reactive, alternative to boronic acids. In most
cases, the ester is thought to have a “masking” function
to the boronic acid and one of the most common
examples is the pinacol ester.[38] Organotin compounds
are a another alternative, as they still hold a prominent
position in cross-coupling chemistry for their stability
and tunability notwithstanding their toxicity.[23] Our
screening of possible alternatives to boronic acids,
Scheme 2, did not indicate that any improvements
might be obtained. Full conversion was only achieved
when the reactant was a boronic acid 2, whilst no
conversion was observed when the correspondent
boronic ester 4 was employed. A yield of 11% was
Scheme 2. Screening experiments varying the leaving group of
the arene moiety. Reaction conditions: 1a (221 μmol), a reagent
(2, 4 or 5) (1.4 equiv.), MnO2 (3 equiv.), bathocuproine L1
(5%), Pd(OAc)2 (5%), ACN (1 mL).
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obtained when the organotin reagent 5 was employed
in the place of boronic acid.
Ligand
The oxidative Heck cross-coupling has been carried
out both in ligand-free[17,34,35] and in ligand-based
reactions.[18,36] The addition of a Pd-chelating species
rises from the need of a better regio- and stereo-
selectivity and of avoiding the accumulation of Pd(0)
species that can agglomerate to form clusters of
unreactive Pd that can slow the rate, or even block, the
coupling reaction.
Traditionally, bidentate nitrogen ligands have been
employed in oxidative Heck reactions due to low cost,
greater stablility to air and moisture and because they
facilitate the oxidation Pd(0)!Pd(II).[37] Since the 1,
10-phenanthroline family of ligands has already proven
to be the suitable for this particular kind of cross-
coupling, we limited our screening to the identification
of which member of this family performed the best
under our reaction conditions. The results of the
screening are presented in Figure 1h.
Initially the most promising ligands were neo-
cuproine L2 and bathophenanthroline L3. Neverthe-
less, the presence of both 2,9-dimethyl and 4,7-
diphenyl substitutions proved to have a synergistic
effect that increased substantially the yield when
bathocuproine L1 was used as a ligand. The combined
action of bathocuproine L1 and palladium in aerobic
oxidations has previously been described.[40] Another
previous report[41] also confirms the positive co-action
of L1 and Pd catalysts in an oxidative Heck approach.
Other Additives
The use of various additives, such as a base or a silver
species, has been previously discussed in the relevant
literature.[39] Contrary to these insights, when the base
K2CO3 was introduced as a part of the reaction
mixture, the reaction was completely inhibited. Ag2O
proved to be detrimental to the performance of the
oxidative Heck coupling reaction, with an overall loss
in yield >20% compared to the reaction run without it.
Scope and Limitation of the Method
The developed oxidative Heck method was explored
by utilizing N-tosyl-4-vinyl-1H-imidazole 1a as sub-
strate and a series of various boronic acids, see
Scheme 3. The method proved to be a general,
selective, and effective strategy to obtain 4-styryl-
imidazoles that tolerate a huge variety of functional
groups. Furthermore, the Z-isomer or the 1,1 substitu-
tion were not observed. Even though the reaction was
carried out with a slight excess of the oxidant MnO2
Scheme 3. Scope and limitation of the oxidative Heck cross-coupling reaction at optimized conditions. Reaction conditions: 1a
(221 μmol), boronic acid 3a, f–z (1.4 equiv.), MnO2 (3 equiv.), bathocuproine (5%), Pd(OAc)2 (5%), ACN (1 mL). nd=not
detected. [a] The reaction was carried out for 8 h with 2 equiv. of boronic acid. [b] The reaction afforded a yield of 39%, but TM
appears to be unstable, since after the purification on HPLC, even more side products were observed. [c] The reaction was
conducted in DMF because the boronic acid was not soluble in ACN or 1,4- dioxane. Traces of TM were detected using LC–MS.
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we observed no oxidation of either the thioether group
(3c), the aldehyde (3 l), and the phenol (3f). The
oxidative Heck cross-coupling reaction proceeded also
with both bromo- and iodo-arenes, in this context it is
worth noting that no Suzuki cross-coupling reaction
took place as a competing/parasite reaction.
The oxidative Heck cross-coupling reaction af-
forded high to excellent yields using 3- and 4-
substitued phenylboronic acids as reagents, and pro-
ceeds with good yields also if functional groups were
installed in the 2-position, even with cumbersome
substituents (3m). In general, electron-rich substituents
on the phenyl boronic acid scaffold afforded higher
conversion than the electron deficient ones. This trend
was observed also with the good yields obtained if
electron-rich heterocyclic boronic acids are employed
compared to the lack of conversion when electron-poor
heterocyclic boronic acids were used. Furthermore, the
reaction only worked in the presence of arylboronic
acids whereas no product was detected when aliphatic
or alkenyl boronic acids were employed. In all
unproductive reaction experiments only the substrate
1a was observed.
In order to extend the scope of the developed
method, an experiment using the 2-vinyl-imidazole 6
as substrate was conducted, Scheme 4. When the
vinylic group was installed on another position on the
imidazole ring, the method operated absolutely perfect
producing target product (E)-2-styryl-1-tosyl-1H-
imidazole 7 in a yield of 92%.
Our method for oxidative Heck cross-coupling was
further explored with other vinyl-N-heterocycles as
substrates, Scheme 5. The reaction was carried out
both on micro-molar and milli-molar scale, which
revealed that the method was scalable.
Overall, the results reveal a high functional group
tolerance for the developed oxidative Heck cross-
coupling method, which includes a mild oxidant
(MnO2), short reaction time, and without acid or base
present.
The option of double substitution on the vinyl
moiety by using an excess of the boronic acid was
explored. The experiment portrayed in Scheme 6,
afforded a product corresponding to either 3 l’ or 3 l,’’
suggesting that a double arylation could be feasible
when carried out with an excess of boronic acid and
MnO2. Indeed, when the reaction was performed with
10 equiv. of boronic acid and 6 equiv. of MnO2,
HPLC-MS and NMR analyses revealed three main
products: the mono-substituted imidazole 3 l, and the
di-substituted imidazoles 3 l’ and 3 l.’’ The formation
of the 1:1 mixture of 3 l’ and 3 l’’ reveals that the
regio-selectivity is lost for the second cross-coupling.
Scheme 4. Oxidative Heck cross-coupling on 1-tosyl-2-vinyl-
1H-imidazole 6 using (221 μmol), phenyl boronic acid 2
(1.4 equiv.), MnO2 (3 equiv.), bathocuproine (5%), Pd(OAc)2
(5%), ACN (1 mL) to achieve (E)-2-styryl-1-tosyl-1H-
imidazole 7.
Scheme 5. Oxidative Heck cross-coupling with vinyl-N-hetero-
cycles 8a–e. Reaction conditions: the vinyl-compound
(2.2 mmol), phenyl boronic acid 2 (1.4 equiv.), MnO2 (3 equiv.),
bathocuproine (5%), Pd(OAc)2 (5%), ACN (10 mL), and 8a–e
(226 μmol), phenyl boronic acid (1.4 equiv.), MnO2 (3 equiv.),
bathocuproine (5%), Pd(OAc)2 (5%), ACN (1 mL).
Scheme 6. The oxidative Heck cross-coupling reaction in the using excess of both boronic acid 2 and oxidant MnO2.
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Mechanism
Based on the observed experimental results, a plausible
reaction mechanism for the Pd catalytic cycle of the
base-free boron oxidative Heck cross-coupling reaction
was outlined, see Scheme 7.
The first step is a trans-metalation that produces the
palladium (II) intermediate �1 , which is in contrast
with other coupling reactions where the boronic acid
first is activated through the formation of an “ate”
complex. The coordination of the alkene is followed
by insertion �2 , β-hydride- �3 and reductive elimina-
tions producing target molecule TM and Pd (0) �4 ,
respectively. Pd (0) is re-oxidized to Pd (II) by MnO2.
Notably 2 equiv. of the oxidant were needed to form
the peroxopalladium complex �5 , which is known to
react with boronic acid[42] to produce complex�6 .
Conclusion
Functionalization of imidazoles is of great importance
for applications in life science and industrial applica-
tions, in particular as NHC ligands for transition metal
catalysis. Functionalization of the nitrogen atoms of
the imidazole ring and the carbon in the 2-position can
be performed relatively smoothly by means of existing
methods in organic synthesis. However, functionaliza-
tion of the backbone of imidazole is more challenging.
Multicomponent reactions producing the imidazole
ring with embedded functionality have been used, but
such a strategy can also be challenging especially if
sterically demanding groups are to be incorporated on
the imidazole backbone (i. e. position 4 and 5).
In this study, the strategy of late stage functionali-
zation has been used. Imidazole or a simple and readily
available functionalized imidazole ring, such as
imidazole carbaldehyde, can be used as the starting
substrate. Hence, with imidazole carbaldehyde as the
starting substrate, we have designed and developed a
regioselective and high yielding method for oxidative
Heck cross-coupling that provides (E)-4-styrylimida-
zole derivatives with broad functional group tolerabil-
ity A method that, moreover revealed potential to be
amended to fit other heterocycles. A substantial differ-
ence from previously disclosed oxidative Heck cross-
coupling methods is that it involves MnO2 as a
terminal oxidant, which is cheap, easy to remove, and
offers selectivity towards oxidation of Pd (0)!Pd (II).
Several factors emerge to be crucial for the success of
the method, amongst these the use of boronic acids in
the place of boronic esters, the presence of the
auxiliary group Tosyl and an adequate combination of
Pd catalyst and ligand. Safe for a small number of
exceptions, the disclosed method provided successful
coupling products in yields ranging from a minimum
of 41% up to 95%. We envision that the unveiled
method will be useful for the construction of more
complex heterocycle-centered frameworks, by either
further functionalization of the olefin, of the functional
groups located on the imidazole/heterocycle or on the
newly bonded aromatic ring.
Experimental Section
General Experimental Information. All reagents and solvents
were purchased from commercial sources and used as received.
Reagent-grade chemicals were purchased from commercial
sources and used without further purification. All reaction
mixtures and samples collected during column chromatography
were monitored by means of TLC analysis (TLC plates Merck
Kieselgel 60 F254). The TLC plates were observed under UV
light at λ 254 nm and λ 365 nm. All final compounds were
purified by either semi-preparative RP-HPLC or by autoflash
chromatography. The HPLC eluting mixtures was of acetonitrile
and H2O (both containing 0.1% Formic acid). Fractions of equal
purity were pooled and dried under nitrogen flow overnight. 1H
and 13C NMR spectra were recorded using a Bruker instruments
AV 500 and Biospin 850SB. High-resolution mass spectra
(HRMS) were performed with a Q-TOF Micro YA263 instru-
ment.
Experimental Procedures.
General Procedures – Oxidative Heck Cross-Cou-
pling
Method A: 1a (55 mg, 221 μmol), bathocuproine (5%, 4 mg,
11 μmol), Pd(OAc)2 (5%, 3 mg, 11 μmol), and the boronic acid
(1.4 equiv., 310 μmol) that was dissolved in acetonitrile (1 mL)
Scheme 7. Proposal for a reaction mechanism for the Pd
catalysed base-free boron oxidative Heck cross-coupling reac-
tion.
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was transferred to a pressure-resistant reaction tube (10 mL).
MnO2 (3 equiv., 58 mg, 665 μmol) was then added and the
reactor tube that was sealed and heated for 4 h at 100 °C. After
cooling, the solvent was evaporated under reduced pressure.
The obtained crude was purified by mean of column chromatog-
raphy packed with silica and an eluent composed of hexane and
ethyl acetate. The highest intensity of UV-absorption is around
300 nm for all the products.
Method B: In a pressure-resistant reaction tube (10 mL), 1a
(55 mg, 221 μmol), bathocuproine (5%, 4 mg, 11 μmol), Pd
(OAc)2 (5%, 3 mg, 11 μmol), the boronic acid (2.0 equiv.,
442 μmol) was dissolved in acetonitrile (1 mL). To the mixture,
MnO2 (3 equiv., 58 mg, 665 μmol) was added and the vial was
sealed and heated for 8 h at 100 °C. After cooling, the solvent
was evaporated under reduced pressure and the crude was
purified through HPLC (water:ACN+0.1% HCOOH). The
highest intensity of UV-absorption is around 300 nm for all the
products.
1-Tosyl-1H-imidazole-4-carbaldehyde[13] [37622-92-7] (0a).
1H-imidazole-4-carbaldehyde (5.00 g, 52.0 mmol) and p-tolue-
nesulfonyl chloride (1 equiv., 9.92 g, 52.0 mmol) were added to
a Schlenk-tube under argon atmosphere. THF (dry, 40 mL) was
then added to dissolve the solids and TEA (1 equiv., 7.26 mL,
5.27 g, 52.0 mmol) was added by a syringe. The reaction
mixture was stirred under argon for 24 h at ambient temperature
and checked through GC-MS. Upon completion of the reaction,
the solvent was evaporated under reduced pressure. The crude
product was extracted from acid water with DCM (3×200 mL),
the organic phases were combined and dried over Na2SO4 to
afford the target compound in a yield of 98% (12.81 g,
51.2 mmol) as a white solid. 1H NMR (500 MHz, CDCl3) δ
9.88 (s, 1H), 8.07 (d, J=1.3 Hz, 1H), 7.94 (d, J=1.3 Hz, 1H),
7.89 (dt, J=8.1, 1.8 Hz, 2H), 7.41 (dt, J=8.1, 1.8 Hz, 2H),
2.47 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 185.59, 147.44,
142.89, 137.28, 133.82, 130.81, 127.77, 121.86, 21.81.
1-Tosyl-4-vinyl-1H-imidazole [185850-13-9] (1a). Under inert
and anhydrous conditions, methyltriphenyl-phosphonium
bromide (1.2 equiv., 8.56 g, 24.0 mmol) was placed in a three-
necks flask and suspended in THF (dry, 30 mL). Then
potassium tert-butoxide in THF (1 M, 1.1 equiv., 2.47 g,
22.0 mL, 22.0 mmol) was added by means of a syringe. The
suspension turns into pale yellow color during the addition.
After 30 min, 0a (5.0 g, 20.0 mmol) was added slowly
(exothermic reaction) to the reaction mixture. The reaction
mixture was stirred for 2 h at 20 °C and controlled by means of
GC-MS. Upon completion of the reaction, the solvent was
evaporated under reduced pressure. The crude product was
extracted from acidic water with DCM (3×200 mL), the
organic phases were combined and dried over Na2SO4.
Purification by means of column chromatography with silica
gel and an eluent system composed of hexane:ethyl acetate=
82:18 provides target compound in a yield of 52% (2.51 g,
10.35 mmol) as a white solid. 1H NMR (500 MHz, CDCl3) δ
7.95 (s, 1H), 7.82 (dt, J=8.4, 1.5 Hz, 2H), 7.35 (dt, J=8.2,
1.5 Hz, 2H), 7.16 (s, J=0.7 Hz, 1H), 6.50 (dd, J=17.4,
11.0 Hz, 1H), 5.92 (dd, J=17.4, 1.4 Hz, 1H), 5.26 (dd, J=11.0,
1.4 Hz, 1H), 2.44 (s, 3H).13C NMR (126 MHz, CDCl3) δ
146.33, 142.77, 136.74, 134.92, 130.45, 127.36, 126.93, 115.85,
113.79, 21.73.
4-Formyl-N,N-dimethyl-1H-imidazole-1-sulfonamide
[140174-48-7] (0b).[13] 1H-imidazole-4-carbaldehyde (5.00 g,
52.0 mmol) and DMAS  Cl (1 equiv., 7.47 g, 5.59 mL,
52.0 mmol) were added to a Schlenk-tube under argon
atmosphere. THF (dry, 30 mL) was then added to dissolve the
mixture and TEA (1 equiv., 7.26 mL, 5.27 g, 52.0 mmol) was
added by a syringe. The reaction mixture was stirred under
argon for 24 h at 20 °C. Afterwards, the solvent was removed
under reduced pressure. The crude product was extracted from
acidic water with DCM (3×200 mL), the organic phases were
combined and dried over Na2SO4 to afford target compound in a
yield of 87% (9.21 g, 45.3 mmol) as a white solid. 1H NMR
(500 MHz, CDCl3) δ 9.96 (s, 1H), 7.96 (d, J=1.2 Hz, 1H), 7.89
(d, J=1.3 Hz, 1H), 2.93 (s, 6H). 13C NMR (126 MHz, CDCl3) δ
185.55, 142.18, 137.58, 122.49, 39.54, 38.20.
N,N-Dimethyl-4-vinyl-1H-imidazole-1-sulfonamide [343880-
85-3] (1b). Methyltriphenylphosphonium bromide (1.2 equiv.,
9.49 g, 26.6 mmol) was transferred to a three-necks round
bottom flask (100 mL) under inert and anhydrous conditions.
Then, was suspended in THF (dry, 30 mL), followed by the
addition of potassium tert-butoxide in THF (1 M, 1.1 equiv.,
2.73 g, 24.4 mL, 24.4 mmol) by a syringe (exothermic reaction).
The suspension turned into a pale-yellow color. After 30 min,
0b (4.5 g, 22.1 mmol) was slowly added (exothermic reaction)
to the mixture. The reaction mixture was stirred for 2 h at 20 °C
and controlled by means of GC-MS. Upon completion of the
reaction, the solvent was evaporated under reduced pressure.
The crude product was extracted from acidic water with DCM
(3×200 mL), the organic phases were combined and dried over
Na2SO4. Purification of isolated product by means of column
chromatography packed with silica gel and an eluent system
composed of hexane:ethyl acetate=75:25 provides target
compound in a yield of 62% (3.41 g, 13.7 mmol) as a white
solid. 1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 7.07 (d, J=
0.8 Hz, 1H), 6.50 (dd, J=17.4, 11.0 Hz, 1H), 5.90 (dd, J=
17.4, 1.4 Hz, 1H), 5.23 (dd, J=11.0, 1.5 Hz, 1H), 2.80 (s, 6H).
13C NMR (126 MHz, CDCl3) δ 141.85, 136.82, 127.08, 115.54,
114.27, 38.19.
1-Trityl-1H-imidazole-4-carbaldehyde [33016-47-6] (0c).[32]
To a 250 mL round-bottomed flask 1H-imidazole-4-carbalde-
hyde (1.20 g, 12.5 mol), trityl chloride (1.1 equiv., 3.83 g,
13.7 mol) were dissolved in acetonitrile (40 mL) and stirred at
20 °C. Afterwards, triethylamine (1.72 equiv., 3.0 mL, 2.17 g,
21.5 mol) was added dropwise and the reaction was stirred
18 h. A mixture of hexane (4 mL) and deionized water (40 mL)
was added and stirred for another 30 min. The slurry was
filtered, and the filter cake was washed with water (2×10 mL)
and dried under reduced pressure to afford target compound as
a white solid in a yield of 84% (3.55 g, 10.5 mmol). 1H NMR
(500 MHz, CDCl3) δ 9.88 (s, 1H), 7.61 (d, J=1.3 Hz, 1H), 7.53
(d, J=1.2 Hz, 1H), 7.41–7.33 (m, 9H), 7.15–7.08 (m, 6H). 13C
NMR (126 MHz, CDCl3) δ 186.62, 141.55, 140.89, 140.62,
129.67, 128.55, 128.40, 126.76, 76.36.
1-Trityl-4-vinyl-1H-imidazole [86803-29-4] (1c). Under inert
and anhydrous conditions, methyltriphenyl-phosphonium
bromide (1.2 equiv., 4.43 g, 12.41 mmol) was transferred to a
three-necks round bottom flask and suspended in THF (dry,
25 mL). Then, potassium tert-butoxide in THF (1 M, 1.1 equiv.,
1.27 g, 11.4 mL, 11.4 mmol) was added by means of a syringe.
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The mixture turned into a pale-yellow color. After 30 min, 0c
(3.5 g, 10.3 mmol) was slowly added (exothermic reaction) to
the mixture. The reaction mixture was stirred for 2 h at 20 °C
and monitored by means of GC-MS. Upon completion of the
reaction, the solvent was evaporated under reduced pressure.
The crude product was extracted from acidic water with DCM
(3×200 mL), the organic phases were combined and dried over
Na2SO4. Purification of isolated product by means of column
chromatography packed with silica gel and an eluent system
composed of hexane:ethyl acetate=88:12 provides target
compound in a yield of 66% (2.30 g, 6.84 mmol) as a white
solid. 1H NMR (500 MHz, CDCl3) δ 7.32 (d, J=1.0 Hz, 1H),
7.28–7.22 (m, 9H), 7.10–7.04 (m, 6H), 6.69 (d, J=1.2 Hz, 1H),
6.47 (dd, J=17.4, 11.0 Hz, 1H), 5.75 (dd, J=17.4, 1.7 Hz,
1H), 5.03 (dd, J=11.0, 1.8 Hz, 1H).13C NMR (126 MHz,
CDCl3) δ 142.35, 139.57, 139.23, 129.79, 128.69, 128.10 (3 C
+1 C), 119.35, 112.15, 75.32.
4-Vinyl-1H-imidazole [3718-04-5][3] (1d). 1-Tosyl-4-vinyl-1H-
imidazole 1a (1.0 g, 4.0 mmol) was transferred to a round-
bottom flask (50 mL) and dissolved in MeOH (10 mL) where-
upon HCl (37%, 2 mL) was added in one portion. The reaction
mixture was refluxed for 2 h. MeOH was removed under
reduced pressure and the crude was extracted with Et2O (2×
100 mL) and HCl solution (1 M, 100 mL). The organic phases
were discarded. The aqueous phase was made alkaline by slow
addition of NaOH (exothermic) and extracted again with Et2O
(3×100 mL). The organic phases were combined, dried over
Na2SO4, to afford target compound in a yield of 85% (323 mg,
3.43 mmol) as a pale yellow solid. 1H NMR (500 MHz, CDCl3)
δ 12.92 (s, 1H), 7.54 (s, 1H), 6.96 (s, 1H), 6.54 (dd, J=17.0,
11.2 Hz, 1H), 5.58 (d, J=17.4 Hz, 1H), 5.01 (d, J=10.6 Hz,
1H). 13C NMR (126 MHz, CDCl3) δ 135.87, 135.57, 126.63,
120.04, 112.11.
1-(Tetrahydro-2H-pyran-2-yl)-4-vinyl-1H-imidazole [NEW]
(1e). 4-Vinyl-1H-imidazole (500 mg, 5.31 mmol) was trans-
ferred to a round-bottomed flask (100 mL) and suspended in
DMF (5 mL) at 20 °C. pTSA (5%, 67 mg, 0.265 mmol) and
DHP (1.5 equiv., 670 mg, 0.73 mL, 7.97 mmol) were then
added. The reaction was capped and heated at 100 °C for 18 h.
The post-reaction mixture was cooled at 20 °C, whereupon the
solvent was removed under reduced pressure. The crude
mixture was extracted from basic water solution (NaOH 1 M,
200 mL) with DCM (2×200 mL). The organic phases were
combined, dried over Na2SO4 and target product was obtained
as a yellow oil in a yield of 92% (875 mg, 4.91 mmol). 1H
NMR (500 MHz, CDCl3) δ 7.60 (s, J=0.8 Hz, 1H), 7.02 (d, J=
0.8 Hz, 1H), 6.59 (dd, J=17.4, 11.0 Hz, 1H), 5.83 (dd, J=
17.5, 1.7 Hz, 1H), 5.17 (dd, J=9.6, 2.4 Hz, 1H), 5.13 (dd, J=
11.0, 1.7 Hz, 1H), 4.08–4.02 (m, 1H), 3.70–3.62 (m, 1H), 2.05–
1.88 (m, 3H), 1.73–1.58 (m, 3H). 13C NMR (126 MHz, CDCl3)
δ 140.90, 135.77, 128.56, 114.47, 112.31, 84.07, 67.72, 31.43,
24.80, 22.35.
(E)-4-Styryl-1-tosyl-1H-imidazole [NEW] (3a). The title
compound was synthesized according to the general procedure
A using the following conditions and quantities: phenylboronic
acid (38 mg). Eluent system composed of hexane:ethyl
acetate=90:10. The title compound was isolated as a white
solid in a yield of 92% (66 mg, 203 μmol). 1H NMR (500 MHz,
CDCl3) δ 7.99 (d, J=0.5 Hz, 1H), 7.84 (dt, J=8.5, 1.7 Hz,
2H), 7.47–7.43 (m, 2H), 7.39–7.29 (m, 5H), 7.26–7.21 (m, 2H),
6.87 (d, J=16.1 Hz, 1H), 2.44 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 146.36, 142.79, 136.95, 136.77, 134.92, 130.51,
130.48, 128.68, 127.88, 127.37, 126.55, 118.21, 113.93, 21.74.
HRMS (ESI) m/z: [M+H] calcd for C18H17N2O2S 325.10107;
found 325.10131.
(E)-N,N-Dimethyl-4-styryl-1H-imidazole-1-sulfonamide
[NEW] (3b). The title compound was synthesized according to
the general procedure A using the following conditions and
quantities: N,N-dimethyl-4-vinyl-1H-imidazole-1-sulfonamide
(55 mg, 273 μmol), phenyl-boronic acid (1.4 equiv., 47 mg,
383 μmol). Eluent system composed of hexane:ethyl acetate=
87:13. The title compound was isolated as a white solid in a
yield of 92% (70 mg, 252 μmol). 1H NMR (500 MHz, CDCl3) δ
7.82 (s, 1H), 7.46–7.39 (m, 2H), 7.35–7.24 (m, 3H), 7.22 – 7.13
(m, 2H), 6.87 (d, J=16.1 Hz, 1H), 2.81 (s, J=6.0 Hz, 6H). 13C
NMR (126 MHz, CDCl3) δ 141.85, 137.03, 136.87, 130.26,
128.71, 127.85, 126.55, 118.37, 114.48, 38.24. HRMS (ESI)
m/z: [M+H] calcd for C13H16N3O2S 278.09632; found
278.09742.
(E)-4-Styryl-1-trityl-1H-imidazole [77705-84-1] (3c). The
title compound was synthesized according to the general
procedure A using the following conditions and quantities: 1-
trityl-4-vinyl-1H-imidazole 1c (56 mg, 166 μmol), phenylbor-
onic acid (1.4 equiv., 28 mg, 233 μmol). Eluent system com-
posed of hexane: ethyl acetate=92:08. The title compound was
isolated as a white solid in a yield of 63% (43 mg, 104 μmol).
1H NMR (500 MHz, CDCl3) δ 7.53 (d, J=1.0 Hz, 1H), 7.44 (d,
J=7.3 Hz, 2H), 7.38–7.27 (m, 12H), 7.25–7.13 (m, 7H), 6.93
(d, J=16.2 Hz, 1H), 6.87 (d, J=1.2 Hz, 1H). 13C NMR
(126 MHz, CDCl3) δ 142.09, 139.28, 138.96, 137.50, 129.78,
128.57, 128.24, 128.20, 127.94, 127.76, 126.29, 119.87, 119.64,
75.68. HRMS (ESI) m/z: [M+H] calcd for C30H25N2
413.20177; found 413.20199.
(E)-4-(2-([1,1’-Biphenyl]-4-yl)vinyl)-1-tosyl-1H-imidazole
[NEW] (3 f). The title compound was synthesized according to
the general procedure A using the following conditions and
quantities: [1,1’-biphenyl]-4-ylboronic acid (61 mg). Eluent
system composed of hexane:ethyl acetate=86:14. The title
compound was isolated as a white solid in a yield of 91%
(81 mg, 202 μmol).1H NMR (500 MHz, CDCl3) δ 8.00 (d, J=
0.4 Hz, 1H), 7.84 (d, J=8.4 Hz, 2H), 7.61–7.55 (m, 4H), 7.52
(d, J=8.3 Hz, 2H), 7.43 (t, J=7.7 Hz, 2H), 7.40–7.30 (m, 4H),
7.25 (d, J=1.3 Hz, 1H), 6.91 (d, J=16.1 Hz, 1H), 2.43 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 146.39, 142.82, 140.60, 136.99,
135.83, 134.92, 130.49, 130.01, 128.82, 127.39 (2 C+ 2 C),
127.37 (2 C+2 C), 127.00, 126.92, 118.26, 114.00, 21.75.
HRMS (ESI) m/z: [M+H] calcd for C24H21N2O2S 401.13237;
found 401.13256.
(E)-4-(4-(Methylthio)styryl)-1-tosyl-1H-imidazole [NEW]
(3g). The title compound was synthesized according to the
general procedure A using the following conditions and
quantities: (4-(methylthio) phenyl)boronic acid (52 mg). Eluent
system composed of hexane: ethyl acetate=87:13. The title
compound was isolated as a white solid in a yield of 89%
(67 mg, 180 μmol).1H NMR (500 MHz, CDCl3) δ 7.98 (s, 1H),
7.83 (d, J=8.4 Hz, 2H), 7.36 (t, J=7.8 Hz, 4H), 7.29–7.18 (m,
4H), 6.82 (d, J=16.0 Hz, 1H), 2.48 (s, J=6.4 Hz, 3H), 2.43 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 146.36, 142.81, 138.25,
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136.96, 134.91, 133.67, 130.47, 129.86, 127.36, 126.93, 126.58,
117.57, 113.80, 21.74, 15.71. HRMS (ESI) m/z: [M+H] calcd
for C19H19N2O2S2 371.08879; found 371.08833.
(E)-4-(4-Methylstyryl)-1-tosyl-1H-imidazole [NEW] (3h).
The title compound was synthesized according to the general
procedure A using the following conditions and quantities: p-
tolylboronic acid (42 mg). Eluent system composed of hexane:
ethyl acetate=90:10. The title compound was isolated as a
white solid in a yield of 81% (61 mg, 180 μmol). 1H NMR
(500 MHz, CDCl3) δ 7.98 (d, J=0.5 Hz, 1H), 7.83 (dt, J=8.4,
1.7 Hz, 2H), 7.37–7.32 (m, 4H), 7.29 (d, J=16.1 Hz, 1H), 7.21
(d, J=1.0 Hz, 1H), 7.13 (d, J=8.0 Hz, 2H), 6.82 (d, J=
16.1 Hz, 1H), 2.43 (s, 3H), 2.34 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 146.32, 142.97, 137.84, 136.91, 134.95, 133.99,
130.46 (2 C+1 C), 129.40, 127.35, 126.48, 117.25, 113.61,
21.73, 21.27. HRMS (ESI) m/z: [M+H] calcd for C19H19N2O2S
339.11672; found 339.11689.
(E)-4-(4-Bromostyryl)-1-tosyl-1H-imidazole [NEW] (3 i). The
title compound was synthesized according to the general
procedure A using the following conditions and quantities: (4-
bromophenyl) boronic acid (62 mg). Eluent system composed
of hexane:ethyl acetate=90:10. The title compound was
isolated as a white solid in a yield of 90% (80 mg, 198 μmol).
1H NMR (500 MHz, CDCl3) δ 7.99 (s, 1H), 7.84 (dt, J=8.6,
1.6 Hz, 2H), 7.44 (dt, J=8.6, 1.7 Hz, 2H), 7.36 (d, J=8.2 Hz,
2H), 7.31 (dt, J=8.5, 1.6 Hz, 2H), 7.27–7.22 (m, 2H), 6.85 (d,
J=16.0 Hz, 1H), 2.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ
146.43, 142.45, 137.03, 135.73, 134.86, 131.81, 130.49, 129.20,
128.00, 127.38, 121.62, 118.90, 114.27, 21.74. HRMS (ESI)
m/z: [M+H] calcd for C18H16BrN2O2S 405.00954; found
405.01439.
(E)-4-(2-(1-Tosyl-1H-imidazol-4-yl)vinyl)phenol [NEW] (3 j).
The title compound was synthesized according to the general
procedure A using the following conditions and quantities: (4-
hydroxyphenyl) boronic acid (43 mg). Eluent system composed
of hexane:ethyl acetate=75:25. The title compound was
isolated as a white solid in a yield of 73% (55 mg, 162 μmol).
1H NMR (500 MHz, CD3CN) δ 7.96 (s, 1H), 7.82 (d, J=
8.4 Hz, 2H), 7.37 (d, J=8.1 Hz, 2H), 7.28 (d, J=8.4 Hz, 2H),
7.13 (d, J=16.1 Hz, 1H), 6.99 (s, 1H), 6.74–6.66 (m, 3H), 2.34
(s, 3H). 13C NMR (126 MHz, CD3CN) δ 156.60, 146.59,
142.82, 136.95, 134.41, 130.22, 129.27, 128.56, 127.58, 126.95,
115.73, 115.14, 113.29, 20.39. HRMS (ESI) m/z: [M+H] calcd
for C18H17N2O3S 341.09740; found 341.09599.
(E)-1-tosyl-4-(2,4,6-trimethylstyryl)-1H-imidazole [NEW]
(3k). The title compound was synthesized according to the
general procedure B using the following conditions and
quantities: mesitylboronic acid (73 mg). The title compound
was isolated as a yellow oil in a yield of 41% (33 mg,
90 μmol).1H NMR (500 MHz, CDCl3) δ 8.00 (s, 1H), 7.85 (d,
J=8.4 Hz, 2H), 7.39–7.33 (m, 3H), 7.19 (s, 1H), 6.87 (s, 2H),
6.38 (d, J=16.4 Hz, 1H), 2.45 (s, 3H), 2.31 (s, 6H), 2.27 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 142.90, 141.76, 136.86,
136.51, 136.21, 131.97, 130.47, 128.78, 128.69, 127.44, 123.24,
117.26, 113.46, 21.75, 21.07, 20.94. HRMS (ESI) m/z: [M+H]
calcd for C21H23N2O2S 367.14802; found 367.14769.
(E)-4-(4-Methoxystyryl)-1-tosyl-1H-imidazole [NEW] (3 l).
The title compound was synthesized according to the general
procedure A using the following conditions and quantities: (4-
methoxyphenyl) boronic acid (47 mg). Eluent system composed
of hexane:ethyl acetate=87:13. The title compound was
isolated as a white solid in a yield of 91% (72 mg, 203 μmol).1H
NMR (500 MHz, CDCl3) δ 7.98 (d, J=0.6 Hz, 1H), 7.83 (dt,
J=8.4, 1.9 Hz, 2H), 7.37 (ddd, J=16.0, 7.6, 4.9 Hz, 4H), 7.30–
7.24 (m, 1H), 7.20 (d, J=0.9 Hz, 1H), 6.87 (dt, J=8.8, 1.9 Hz,
2H), 6.73 (d, J=16.1 Hz, 1H), 3.81 (s, 3H), 2.43 (s, 3H). 13C
NMR (126 MHz, CDCl3) δ 159.49, 146.29, 143.08, 134.97,
130.44, 130.08, 129.57, 127.80, 127.34, 116.13, 114.51, 114.13,
113.30, 55.31, 21.72. HRMS (ESI) m/z: [M+H] calcd for
C19H19N2O3S 355.11164; found 355.11280.
(E)-4-(3-methoxystyryl)-1-tosyl-1H-imidazole [NEW] (3m).
The title compound was synthesized according to the general
procedure A using the following conditions and quantities: (3-
methoxyphenyl) boronic acid (47 mg). Eluent system composed
of hexane:ethyl acetate=87:13. The title compound was
isolated as a white solid in a yield of 85% (67 mg, 189 μmol).1H
NMR (500 MHz, CDCl3) δ 7.99 (d, J=0.6 Hz, 1H), 7.83 (dt,
J=8.4, 1.7 Hz, 2H), 7.39–7.21 (m, 6H), 7.05 (d, J=7.7 Hz,
1H), 7.00–6.97 (m, 1H), 6.86 (d, J=16.0 Hz, 1H), 6.83–6.79
(m, 1H), 3.82 (s, 3H), 2.44 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 159.85, 146.38, 142.70, 138.22, 136.96, 134.91,
130.48, 130.40, 129.65, 127.37, 119.25, 118.56, 114.01, 113.55,
111.80, 55.22, 21.74. HRMS (ESI) m/z: [M+H] calcd for
C19H19N2O3S 355.11164; found 355.11180.
(E)-4-(2-Methoxystyryl)-1-tosyl-1H-imidazole [NEW] (3n).
The title compound was synthesized according to the general
procedure A using the following conditions and quantities: (2-
methoxyphenyl) boronic acid (47 mg). Eluent system composed
of hexane:ethyl acetate=87:13.The title compound was isolated
as a white solid in a yield of 71% (56 mg, 158 μmol). 1H NMR
(500 MHz, CDCl3) δ 7.99 (d, J=0.6 Hz, 1H), 7.83 (dt, J=8.4,
1.6 Hz, 2H), 7.60 (d, J=16.3 Hz, 1H), 7.47 (dd, J=7.6, 1.6 Hz,
1H), 7.35 (d, J=8.2 Hz, 2H), 7.25–7.20 (m, 2H), 6.97–6.91 (m,
2H), 6.88 (d, J=8.2 Hz, 1H), 3.86 (s, 3H), 2.44 (s, 3H). 13C
NMR (126 MHz, CDCl3) δ 157.22, 146.26, 143.49, 136.88,
135.01, 130.43, 128.87, 127.34, 127.11, 125.81, 125.78, 120.63,
119.08, 113.58, 110.92, 55.38, 21.72. HRMS (ESI) m/z: [M+
H] calcd for C19H19N2O3S 355.11164; found 355.11197.
(E)-2-(2-(1-Tosyl-1H-imidazol-4-yl)vinyl)benzonitrile [NEW]
(3o). The title compound was synthesized according to the
general procedure B using the following conditions and
quantities: (2-methoxyphenyl)boronic acid (65 mg). The title
compound was isolated as a white solid in a yield of 53%
(41 mg, 117 μmol). 1H NMR (500 MHz, CDCl3) δ 8.01 (d, J=
0.8 Hz, 1H), 7.86 (dt, J=8.5, 1.7 Hz, 2H), 7.66 (d, J=8.1 Hz,
1H), 7.64 (dd, J=7.8, 1.0 Hz, 1H), 7.59–7.52 (m, 2H), 7.38 (d,
J=8.5 Hz, 3H), 7.32 (td, J=7.7, 1.1 Hz, 1H), 7.10 (d, J=
16.0 Hz, 1H), 2.45 (s, 3H). 13C NMR (214 MHz, CDCl3) δ
146.54, 141.90, 140.00, 137.08, 133.38, 132.74, 130.55, 130.03,
129.04, 127.71, 127.45, 125.95, 125.91, 123.48, 117.97, 115.19,
21.76. HRMS (ESI) m/z: [M+Na] calcd for C19H15NaN3O2S
372.07827; found 372.07855.
(E)-4-(2-(1-Tosyl-1H-imidazol-4-yl)vinyl)benzaldehyde
[NEW] (3p). The title compound was synthesized according to
the general procedure A using the following conditions and
quantities: (4-formyl-phenyl)boronic acid (46 mg). Eluent sys-
tem composed of hexane:ethyl acetate=87:13. The title
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compound was isolated as a white solid in a yield of 95%
(74 mg, 210 μmol).1H NMR (500 MHz, CDCl3) δ 9.97 (s, 1H),
8.01 (s, 1H), 7.90–7.79 (m, 4H), 7.59 (d, J=8.2 Hz, 2H), 7.40–
7.34 (m, 3H), 7.32 (s, 1H), 7.02 (d, J=16.0 Hz, 1H), 2.44 (s,
3H). 13C NMR (126 MHz, CD3CN) δ 186.27, 141.24, 137.55,
136.82, 131.86, 130.17, 129.44, 125.23, 124.92, 123.74, 122.10,
121.63, 116.25, 109.87, 16.45. HRMS (ESI) m/z: [M+H] calcd
for C19H17N2O3S 353.09599; found 353.09772.
(E)-4-(2-([1,1’-Biphenyl]-2-yl)vinyl)-1-tosyl-1H-imidazole
[NEW] (3q). The title compound was synthesized according to
the general procedure B using the following conditions and
quantities: [1,1’-biphenyl]-2-ylboronic acid (88 mg). The title
compound was isolated as a white solid in a yield of 65%
(58 mg, 145 μmol).1H NMR (850 MHz, CDCl3) δ 7.92 (d, J=
0.8 Hz, 1H), 7.82 (dt, J=8.5, 1.8 Hz, 2H), 7.66 (dd, J=7.5,
1.0 Hz, 1H), 7.42–7.39 (m, 2H), 7.37–7.31 (m, 7H), 7.29 (d,
J=16.0 Hz, 1H), 7.18 (d, J=1.2 Hz, 1H), 6.81 (d, J=16.0 Hz,
1H), 2.44 (s, 3H). 13C NMR (214 MHz, CDCl3) δ 146.31,
142.99, 141.36, 140.73, 136.82, 134.91, 134.89, 130.45, 130.43,
129.78, 129.49, 128.18, 127.73, 127.50, 127.39, 127.19, 127.16,
125.87, 119.52, 113.70, 21.74. HRMS (ESI) m/z: [M+H] calcd
for C24H22N2O2S 401.13237; found 401.13287.
(E)-4-(4-Iodostyryl)-1-tosyl-1H-imidazole [NEW] (3r). The
title compound was synthesized according to the general
procedure A using the following conditions and quantities: (4-
Iodophenyl)boronic acid (77 mg). Eluent system composed of
hexane:ethyl acetate=90:10. The title compound was isolated
as a white solid in a yield of 71% (71 mg, 158 μmol).1H NMR
(500 MHz, CDCl3) δ 7.99 (s, 1H), 7.83 (dt, J=8.4, 1.7 Hz, 2H),
7.65 (dt, J=8.4, 1.8 Hz, 2H), 7.36 (d, J=8.5 Hz, 2H), 7.23 (d,
J=16.3 Hz, 2H), 7.18 (dt, J=8.8, 1.9, 1.9 Hz, 2H), 6.86 (d, J=
16.0 Hz, 1H), 2.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ
146.44, 142.42, 137.77, 137.03, 136.30, 134.86, 130.49, 129.31,
128.22, 127.38, 118.99, 114.32, 93.12, 21.75. HRMS (ESI) m/z:
[M+H] calcd for C18H16IN2O2S 450.99772; found 450.99980.
(E)-4-(4-Fluorostyryl)-1-tosyl-1H-imidazole [NEW] (3s). The
title compound was synthesized according to the general
procedure A using the following conditions and quantities: (4-
fluorophenyl) boronic acid (43 mg). Eluent system composed of
hexane:ethyl acetate=90:10. The title compound was isolated
as a white solid in a yield of 94% (71 mg, 207 μmol). 1H NMR
(500 MHz, CDCl3) δ 7.99 (s, 1H), 7.86–7.81 (m, 2H), 7.44–
7.38 (m, 2H), 7.36 (d, J=8.2 Hz, 2H), 7.28 (d, J=16.2 Hz,
1H), 7.23 (s, 1H), 7.05–6.98 (m, 2H), 6.78 (d, J=16.0 Hz, 1H),
2.43 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 162.46 (d, J=
247.6 Hz), 146.39, 142.61, 136.96, 134.89, 132.97 (d, J=
3.5 Hz), 130.48, 129.28, 128.06 (d, J=7.8 Hz), 127.36, 117.99
(d, J=2.0 Hz), 115.65 (d, J=21.6 Hz), 113.93, 21.74. HRMS
(ESI) m/z: [M+H] calcd for C18H16FN2O2S 343.09165; found
343.09199.
(E)-4-(3-Nitrostyryl)-1-tosyl-1H-imidazole [NEW] (3 t). The
title compound was synthesized according to the general
procedure B using the following conditions and quantities: (3-
nitrophenyl)boronic acid (74 mg). The title compound was
isolated as a white solid in a yield of 53% (43 mg, 116 μmol).
1H NMR (500 MHz, CDCl3) δ 8.32 (t, J=1.9 Hz, 1H), 8.08
(ddd, J=8.2, 2.2, 0.9 Hz, 1H), 8.01 (s, 1H), 7.85 (dt, J=8.4,
1.8 Hz, 2H), 7.74–7.70 (m, 1H), 7.50 (t, J=8.0 Hz, 1H), 7.41–
7.30 (m, 4H), 7.00 (d, J=16.0 Hz, 1H), 2.45 (s, 3H). 13C NMR
(126 MHz, CDCl3) δ 148.74, 146.57, 141.83, 138.64, 137.17,
134.76, 132.55, 130.55, 129.63, 127.85, 127.43, 122.25, 121.19,
120.65, 115.16, 21.76. HRMS (ESI) m/z: [M+H] calcd for
C18H16N3O4S 370.08615; found 370.08744.
(E)-4-(2-(Furan-2-yl)vinyl)-1-tosyl-1H-imidazole [NEW]
(3u). The title compound was synthesized according to the
general procedure B using the following conditions and
quantities: Furan-2-ylboronic acid (50 mg). The title compound
was isolated as a white solid in a yield of 56% (39 mg,
124 μmol). 1H NMR (500 MHz, CDCl3) δ 7.96 (s, 1H), 7.83 (dt,
J=8.4, 1.8 Hz, 2H), 7.39–7.33 (m, 3H), 7.19 (d, J=1.0 Hz,
1H), 7.10 (d, J=15.8 Hz, 1H), 6.77 (d, J=15.8 Hz, 1H), 6.39
(dd, J=3.3, 1.8 Hz, 1H), 6.32 (d, J=3.3 Hz, 1H), 2.44 (s, 3H).
The compound 19a decomposed and we were not able to record
13C NMR data and HRMS (ESI) for this compound.
(E)-4-(2-(Thiophen-2-yl)vinyl)-1-tosyl-1H-imidazole [NEW]
(3v). The title compound was synthesized according to the
general procedure B using the following conditions and
quantities: Thiophen-2-ylboronic acid (57 mg). The title com-
pound was isolated as a white solid in a yield of 54% (40 mg,
121 μmol). 1H NMR (850 MHz, CDCl3) δ 8.00 (s, 1H), 7.85 (d,
J=8.4 Hz, 2H), 7.46 (d, J=15.7 Hz, 1H), 7.39 (d, J=8.3 Hz,
2H), 7.22 (s, 1H), 7.20 (d, J=5.0 Hz, 1H), 7.06 (d, J=3.5 Hz,
1H), 7.00 (dd, J=5.0, 3.6 Hz, 1H), 6.70 (d, J=15.7 Hz, 1H),
2.47 (s, J=6.8 Hz, 3H). 13C NMR (214 MHz, CDCl3) δ 146.36,
142.37, 142.21, 136.97, 134.89, 130.46, 127.65, 127.35, 126.69,
124.66, 123.66, 117.73, 113.77, 21.74. HRMS (ESI) m/z: [M+
H] calcd for C16H15N2O2S2 331.05749; found 331.05888.
1-Tosyl-1H-imidazole-2-carbaldehyde [155742-57-7].[13] 1H-
imidazole-2-carbaldehyde (5.00 g, 52.0 mmol) and p-toluene-
sulfonyl chloride (1 eq., 9.92 g, 52.0 mmol) were added to a
Schlenk-tube under argon atmosphere. THF (dry, 40 mL) was
added to dissolve the solids. Then, TEA (1 equiv., 7.26 mL,
5.27 g, 52.0 mmol) was added by means of a syringe. The
reaction mixture was stirred under argon for 24 h at ambient
temperature and checked through GC-MS. Upon completion of
the reaction, the solvent was evaporated under reduced pressure.
The crude product was extracted from acid water with DCM
(3×200 mL), the organic phases were reunited and dried over
Na2SO4 to afford the desired compound in a yield of 96%
(12.45 g, 49.7 mmol) as a white solid. The NMR revealed an
impure product with traces of p-toluenesulfonyl chloride present
in the product. However, this impurity does not affect the
following reaction and the isolated product was used in the
following Wittig reaction step. NMR data of the compound was
previously disclosed.[43]
1-Tosyl-2-vinyl-1H-imidazole [NEW] (6). Methyl-triphenyl-
phosphonium bromide (1.2 equiv., 8.56 g, 24.0 mmol) was
transferred to a three-necks round bottom flask (100 mL) under
inert and anhydrous conditions. Then, the solid was suspended
in THF (dry, 30 mL). Potassium tert-butoxide in THF (1 M,
1.1 equiv., 2.47 g, 22.0 mL, 22.0 mmol) was added by means of
a syringe (exothermic reaction). The reaction mixture turns into
a pale-yellow color. After 30 min, 1d (5.0 g, 20.0 mmol) was
slowly (exothermic reaction) added to the mixture and stirred
for 2 h at 20 °C and monitored by means of GC-MS. Upon
completion of the reaction, the solvent was evaporated under
reduced pressure. The crude product was extracted from acid
water with DCM (3 × 200 mL), the organic phases were
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combined and dried over Na2SO4. Finally, purification by means
of column chromatography packed with silica gel and an eluent
system composed of hexane:ethyl acetate=82:18 provides the
target compound in a yield of 45% (2.24 g, 9.0 mmol) as a
white solid. 1H NMR (500 MHz, CDCl3) δ 7.67 (dt, J=8.4,
1.8 Hz, 2H), 7.35 (d, J=1.6 Hz, 1H), 7.23 (d, J=8.4 Hz, 2H),
7.05 (dd, J=17.2, 11.1 Hz, 1H), 6.92 (d, J=1.6 Hz, 1H), 6.15
(dd, J=17.2, 1.6 Hz, 1H), 5.42 (dd, J=11.1, 1.5 Hz, 1H), 2.31
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 146.15, 145.91, 135.08,
130.30, 129.25, 127.23, 122.89, 122.06, 119.60, 21.66.
(E)-2-Styryl-1-tosyl-1H-imidazole [NEW] (7). The title com-
pound was synthesized according to the general procedure A
using the following conditions and quantities: 1-tosyl-2-vinyl-
1H-imidazole (55 mg, 221 μmol), phenyl-boronic acid (38 mg).
Eluent system composed of hexane:ethyl acetate= 90:10. The
title compound was isolated as a white solid in a yield of 92%
(66 mg, 203 μmol). 1H NMR (500 MHz, CDCl3) δ 7.78 (dt, J=
8.4, 1.7 Hz, 2H), 7.63–7.50 (m, 4H), 7.46 (d, J=1.6 Hz, 1H),
7.42–7.37 (m, 2H), 7.36–7.29 (m, 3H), 7.06 (d, J=1.6 Hz, 1H),
2.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 146.52, 146.13,
136.38, 135.98, 135.23, 130.36, 129.59, 129.03, 128.86, 127.30,
127.23, 119.55, 113.47, 21.69. HRMS (ESI) m/z: [M+H] calcd
for C18H17N2O2S 325.10107; found 325.10133.
(E)-4-Styrylpyridine [5097-93-8] (9a). The title compound
was synthesized according to the general procedure A with
some amendments for up-scaled use. In particular, the following
conditions and quantities were used: a pressure-resistant
reaction tube (20 mL) was charged with 4-vinylpyridine
(231 mg, 2.20 mmol), bathocuproine (40 mg), Pd(OAc)2
(25 mg), phenyl-boronic acid (375 mg), MnO2 (535 mg), and
ACN (10 mL). Eluent system composed of hexane:ethyl
acetate=90:10. The title compound was isolated as a white
solid in a yield of 80% (317 mg, 1.75 mmol). 1H NMR
(500 MHz, CDCl3) δ 8.56 (dd, J=4.5, 1.6 Hz, 2H), 7.71–7.64
(m, 2H), 7.60–7.53 (m, 3H), 7.47–7.40 (m, 2H), 7.35 (dt, J=
7.3, 1.0, 1.0 Hz, 1H), 7.27 (d, J=16.5 Hz, 1H). 13C NMR
(126 MHz, CDCl3) δ 150.01, 144.21, 136.13, 132.96, 128.80,
128.62, 127.04, 125.95, 120.84. HRMS (ESI) m/z: [M+H]
calcd for C13H11N 182.09697; found 182.09723.
(E)-5-Styrylpyrimidine [35782-34-4] (9b). The title compound
was synthesized according to the general procedure B using the
following conditions and quantities: 5-vinylpyrimidine (24 mg,
226 μmol), phenyl-boronic acid (55 mg). The title compound
was isolated as an off-white solid in a yield of 73% (66 mg,
203 μmol). 1H NMR (500 MHz, CDCl3) δ 9.09 (s, 1H), 8.87 (s,
2H), 7.54 (d, J=7.4 Hz, 2H), 7.40 (t, J=7.5 Hz, 2H), 7.37–
7.31 (m, J=7.3 Hz, 1H), 7.24 (d, J=16.6 Hz, 1H), 7.00 (d, J=
16.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 157.21, 154.27,
135.99, 132.87, 131.04, 128.92, 128.87, 126.88, 121.12.
(E)-2-Styrylfuran [1202-49-9] (9c). The title compound was
synthesized according to the general procedure B using the
following conditions and quantities: 2-vinylfuran (50 mg,
531 μmol), bathocuproine (10 mg), Pd(OAc)2 (6 mg) phenyl-
boronic acid (130 mg), MnO2 (139 mg), and ACN (2 mL). The
title compound was observed in traces in GC-MS analysis but
was not isolated (<1% yield).
(E)-2-Styrylthiophene [26708-50-9] (9d). The title compound
was synthesized according to the general procedure B using the
following conditions and quantities: 2-vinyltiophene (50 mg,
454 μmol), bathocuproine (8 mg), Pd(OAc)2 (5 mg) phenyl-
boronic acid (111 mg) MnO2 (118 mg), and ACN (2 mL). The
title compound was isolated as an off-white solid in a yield of
yield 77% (65 mg, 349 μmol). 1H NMR (500 MHz, CDCl3) δ
7.41–7.37 (m, 2H), 7.29–7.24 (m, 2H), 7.19–7.10 (m, 3H), 6.99
(d, J=3.6 Hz, 1H), 6.93 (dd, J=5.1, 3.6 Hz, 1H), 6.86 (d, J=
16.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 142.90, 136.98,
128.71, 128.35, 127.61, 126.31, 126.11, 124.35, 121.80
(E)-1,2-Diphenylethene [103-30-0] (9e). The title compound
was synthesized according to the general procedure A with
some amendments for up-scaled use. In particular, the following
conditions and quantities were used: a pressure-resistant
reaction tube (20 mL) was charged with styrene (208 mg,
2.00 mmol), bathocuproine (36 mg), Pd(OAc)2 (22 mg), phenyl-
boronic acid (341 mg), MnO2 (521 mg), and ACN (10 mL).
Eluent system composed of hexane:ethyl acetate=90:10. White
solid. Isolated yield 62% (224 mg, 1.24 mmol). 1H NMR
(500 MHz, CDCl3) δ 7.54–7.50 (m, 4H), 7.36 (dd, J=8.5,
6.9 Hz, 4H), 7.28–7.23 (m, 2H), 7.11 (s, 2H). 13C NMR
(126 MHz, CDCl3) δ 137.34, 128.70, 127.63, 126.53.
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